BIOATLA, INC. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
BIOATLA, INC. (BCAB) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $6.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-08-13
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-30 was $6.50M.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $2.00M.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-06-30 was $0.00.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2025 was $2.00M, a 81.82% decline from fiscal 2024.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2024 was $11.00M.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $0.00.
- BIOATLA, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.50M 10-Q · filed 2026-08-13 | $6.50M 10-Q · filed 2026-08-13 | ||
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.00M derived: sum of 2 quarters · filed 2026-03-31 | $2.00M derived: sum of 3 quarters · filed 2026-08-13 | $2.00M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $11.00M derived: sum of 2 quarters · filed 2026-03-31 | $11.00M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $11.00M 10-Q · filed 2025-11-13 | $11.00M 10-Q · filed 2025-11-13 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 10-K · filed 2025-03-28 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $250.00K derived: sum of 3 quarters · filed 2023-03-23 | $250.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $250.00K derived: sum of 2 quarters · filed 2022-08-09 | $250.00K 10-Q · filed 2022-11-04 | $250.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $250.00K 10-Q · filed 2022-08-09 | $250.00K 10-Q · filed 2022-08-09 | $250.00K derived: sum of 3 quarters · filed 2022-08-09 | $400.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $150.00K derived: sum of 3 quarters · filed 2022-02-28 | $340.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $150.00K derived: sum of 2 quarters · filed 2022-02-28 | $340.00K derived: sum of 3 quarters · filed 2022-02-28 | $429.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $150.00K 10-Q · filed 2021-11-15 | $340.00K derived: sum of 2 quarters · filed 2021-11-15 | $429.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $190.00K 10-Q · filed 2021-08-13 | $279.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $89.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $5.20M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |